Veritas Pharma Inc.

(VRT:CNX)

By |

Veritas Pharma is led by a strong management and a renowned team of scientists to address the critical need for real science to support medical marijuana claims. Our mission is to develop and commercialize the most effective cannabis strains. Veritas Cannabis clinical development pipeline include:

  • Chronic Pain (e.g. cancer pain)
  • Nausea & Vomiting
  • Muscle Spasms
  • Epilepsy
  • Post-Traumatic Stress Disorder (PTSD)


The Market

As public perception and patient preference continues to trend positively towards the medical use of marijuana, many analyst believe that the currently $2.9bn industry* is on the verge of rapid growth. This projected growth is further assisted by the continued liberalization of cannabis laws at the national and state levels within North America. Canada has a national medical cannabis program and a newly elected prime minister who has stated his intents on legalizing recreational use of cannabis. In the United States, thus far 39 states have legalized cannabis either for recreational or medicinal use, despite Cannabis being federally classified as a schedule 1 substance under the Controlled Substances Act.

Veritas’ immediate aim is to develop cannabis strains that specifically target cancer pain and nausea. Currently, cancer pain is the largest segment of the opioid market. However, with the increasing public concern over the continued use of opioids for pain treatment a trend towards alternative treatments is expected.

If we can say, Yes, these particular cultivars are effective and work and can save patients’ lives or make lives better, improving their quality of life. That’s something worth investigating and pursuing. That’s what drives me.
- Dr. Dom Spina Director

Our Research and development approach

Veritas innovative research and development approach aims to solve the critical need for real science to support claims surrounding medical marijuana. Our scientific approach combined with our strategic alliances intends to effectively address the concerns over the medical industry’s varied output in content and quality, potency and efficacy.

Three-pronged Approach to Research and Development:

First, we aim to chemically profile different marijuana cultivars.

Subsequently, those same cultivars will pharmacologically be profiled in the search for disease specific strains.

Finally, we aim to perform clinical trials to establish the clinical utility of each cultivar.

This unique approach has the advantage of being low cost, and allows for faster market entry, providing doctors and patients with conclusive scientific evidence to recommend and use our proprietary medical cannabis strains with confidence. Similarly, the presence of conclusive scientific evidence could potentially develop the platform allowing coverage through medical insurance providers.

  • de Bruin D, Ahmad T, Avendano JE, Sajanial M, Edelstein A, Ryskin M. 2015. Bank of America Report Is Bullish on Cannabis Testing. Biotech Business Week, Dec. 3, ,pp. 1–45

Medicinal Cannabis Industry Approach

The medicinal cannabis industry currently consists of either medical marijuana producers or the traditional pharmaceutical approach. The pharmaceutical approach traditionally involves the study of individual cannabinoids as target molecules for drug discovery. This approach has generally proven to be both costly and time consuming. The rapidly growing medical marijuana industry on the other hand commonly develops inconsistent products as pharmaceutical grade quality assurance/quality control (QA/QC) is not present. Additionally, these products lack solid scientific proof of effectiveness.

Veritas’ Approach

Veritas innovative research and development approach aims to solve the critical need for real science to support claims surrounding medical marijuana. Our scientific approach combined with our strategic alliances intends to effectively address the concerns over the medical industry’s varied output in content and quality, potency and efficacy.

Veritas has developed a three-pronged approach to research and development:

  • First, we aim to chemically profile different marijuana cultivars.
  • Subsequently, those same cultivars will pharmacologically be profiled in the search for disease-specific strains.
  • Finally, we aim to perform clinical trials to establish the clinical utility of each cultivar.

This unique approach has the advantage of being low cost, and allows for faster market entry, providing doctors and patients with conclusive scientific evidence to recommend and use medical marijuana with confidence. Similarly, the presence of conclusive scientific evidence could potentially develop the platform allowing coverage through medical insurance providers.

Management

Dr. Lui Franciosi, PhD Dr. Lui Franciosi, PhD
Chief Executive Officer

Dr. Franciosi has more than 20 years of experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he acted as the Chief Operating Officer at Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior to Verona Pharma, Dr. Franciosi completed his post-doctoral research in COPD progression modeling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. He obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada – and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.

David Alexander, CPA /CADavid Alexander, CPA /CA
Chief Financial Officer

Mr. Alexander holds a Bachelor of Commerce in Finance from The University of British Columbia. His past achievements include; CFO of Arakis Energy Corporation, an international oil and gas development company, and managed the company’s growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company (Nasdaq: CRME).

Additional Information

Veritas Pharma Inc.

Profile

In an industry projected to have substantial growth within next few years, Veritas is among the first to apply a comprehensive scientific approach behind medical marijuana claims. Our mission is to develop the most effective proprietary cannabis strains for specific disease conditions, and to provide doctors and patients with conclusive scientific evidence to recommend and use medical marijuana with confidence.

Contact Information

Website: veritaspharmainc.com
Main Phone: (416) 918-6785
Address: 101 – 2386 East Mall
Address 2: University of British Columbia
State: BC
City / Town: Vancouver
Country: CAN
Postal Code: V6T 1Z3

Issuer Information

Exchange: CNQ
CEO: Dr. Lui Franciosi, PhD
Issuer Type: CS - Common Stock
Sector/Industry: Healthcare
NAICS: Medicinal and Bo
$ 0.36 $ 0.04 (14.29%)
Last Price 0.36 Change $ 0.04 Change % 14.29 Tick N/A
Bid 0.36 Bid Size 500.00 Ask 0.37 Ask Size 12,000.00
Open 0.32 High 0.36 Low 0.32 Prev Close 0.32
Last Trade Volume 234,940 52 Wk Hi 0.65 52 Wk Low 0.03
Market Cap 8.8 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 24,318,000.00 EPS (TTM) -0.06 PE Ratio N/A Exchange CSE